Research And Development
Health
Pharmaceutical

Array BioPharma

$24.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.19 (0.78%) Pre-Market
+$0.19 (0.78%) Pre-Market

Why Robinhood?

You can buy or sell ARRY and other stocks, options, ETFs, and crypto commission-free!

About

Array BioPharma, Inc. engages in the research, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other high-burden diseases. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. Read More The company was founded by Kevin Koch, Anthony Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO.

Employees
298
Headquarters
Boulder, Colorado
Founded
1998
Market Cap
5.28B
Price-Earnings Ratio
Dividend Yield
Average Volume
2.77M
High Today
$24.50
Low Today
$23.78
Open Price
$23.78
Volume
839.13K
52 Week High
$24.56
52 Week Low
$12.56

Collections

Research And Development
Health
Pharmaceutical
Cancer Prevention
Biotechnology
Technology

News

The Motley FoolMar 6

Why Array BioPharma Stock Soared 22.9% in February

What happened Shares of Array BioPharma (NASDAQ:ARRY) gained 22.9% last month, according to data from S&P Global Market Intelligence. The stock is up 63% in 2019 through March 5. The Boulder, Colorado-based biotech is focused on developing targeted small molecule drugs to treat patients afflicted with cancer. For some context, the S&P 500 index returned 3.2% in February and has returned 11.7% so far this year. So what We can attribute Array BioPharma stock's strong performance last month to the company...

722
PR NewswireMar 5

Array BioPharma to Present at the 39th Annual Cowen Health Care Conference

BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the 39th Annual Cowen Health Care Conference in Boston. The public is welcome to participate in the conference through a webcast on the Array BioPharma website. Event: 39th Annual Cowen Health Care Conference Presenter: Ron Squarer, Chief Executive Officer, Array BioPharma Date: Tuesday, March 12, 2019 Time: 12:00 p.m. Eastern Time Webcast: http://ws...

54
Yahoo FinanceMar 4

Recent Analysis Shows Array BioPharma, Nabors Industries, Brinker International, Piedmont Office Realty Trust, Och-Ziff Capital Management Group, and Franklin Street Properties Market Influences — Ren

NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Array BioPharma Inc.

123

Earnings

-$0.25
-$0.18
-$0.12
-$0.05
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected May 8, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.